Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease : experience from the Phase 3 ATTRACT study

dc.contributor.author	Hughes, Derralynn A.	pt_BR
dc.contributor.author	Nicholls, Kathleen M.	pt_BR
dc.contributor.author	Sunder-Plassmann, G.	pt_BR
dc.contributor.author	Jovanovic, Ana	pt_BR
dc.contributor.author	Feldt-Rasmussen, Ulla	pt_BR
dc.contributor.author	Schiffmann, Raphael	pt_BR
dc.contributor.author	Giugliani, Roberto	pt_BR
dc.contributor.author	Jain, Vipul	pt_BR
dc.contributor.author	Viereck, Christopher	pt_BR
dc.contributor.author	Castelli, Jeffrey P.	pt_BR
dc.contributor.author	Skuban, Nina	pt_BR
dc.contributor.author	Barth, Jay	pt_BR
dc.contributor.author	Bichet, Daniel G.	pt_BR
dc.date.accessioned	2019-10-25T03:46:43Z	pt_BR
dc.date.issued	2019	pt_BR
dc.identifier.issn	1552-4833	pt_BR
dc.identifier.uri	http://hdl.handle.net/10183/200996	pt_BR
dc.format.mimetype	application/pdf	pt_BR
dc.language.iso	eng	pt_BR
dc.relation.ispartof	American journal of medical genetics. Part A. Hoboken, N.J. : Wiley-Blackwell. Vol. 179A (2019), p. 1069–1073	pt_BR
dc.rights	Open Access	en
dc.subject	Terapia de reposição de enzimas	pt_BR
dc.subject	Tratamento farmacológico	pt_BR
dc.subject	Substituição de medicamentos	pt_BR
dc.subject	Doença de Fabry	pt_BR
dc.subject	Estudo clínico	pt_BR
dc.title	Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease : experience from the Phase 3 ATTRACT study	pt_BR
dc.type	Artigo de periódico	pt_BR
dc.identifier.nrb	001104115	pt_BR
dc.type.origin	Estrangeiro	pt_BR

Este item está licenciado na Creative Commons License